Targeted radiotherapy of neuroblastoma: future directions

Received: October 15, 2017; Accepted: November 10, 2017; Published: November 13, 2017 Neuroblastoma is a malignancy predominantly of infancy. It originates most commonly in the adrenal gland and affects a hundred individuals per year in the UK. Half of neuroblastomas are highly aggressive, disseminated throughout the body of the patient and characterised by unresponsiveness to therapy or early relapse if remission is achieved. High-risk neuroblastoma is responsible for 12% of paediatric cancer fatalities and new treatments are urgently needed [1].